Newsroom

Absci 1d ago

📣 A milestone in our partnership with AMD: Absci's Origin antibody-design platform now runs on AMD Instinct™ GPUs. Scoring antibody designs with co-folding is one of the most computationally expensive tasks in our Origin platform. Working side by side with AMD, we integrated their open-source Triton kernels into AbsciBind, our co-folding binding filter, and achieved a 3x speedup over our production baseline on AMD Instinct™ GPUs, with no loss in output quality. We are also pleased with AMD's efforts to bring important tools like MMseqs2 to their ROCm platform, allowing us to run AbsciBind end-to-end on AMD. As a result, we've brought a dedicated AMD Instinct™ MI300X cluster online, and it's now the inference compute behind advancing Origin to its next-generation version, Origin-3. More news to come as we continue scaling our mission to accelerate AI antibody design and discovery. ▸ Learn More Full Story: https://lnkd.in/gy4ZNM3Z About MMseqs2: https://lnkd.in/ga7cR8mv

View post on LinkedIn

Absci 4d ago

We’re hiring top-tier talent to join us in advancing our pipeline and unlocking differentiated biology through generative AI. Several roles are open across AI Research & Engineering, Clinical Research & Operations, Legal, and Project Management: • Staff/Principal AI Scientist, Virtual Tissue • Senior/Staff AI Scientist, Antibody Design • Vice President, Clinical Operations • Senior Director, Inspection Readiness • Drug Discovery Resource Outsourcing Manager • Director, Project Management • Director, Regulatory & Compliance 🧬 If you're ready to make an impact, apply today: https://lnkd.in/gR8pdj7h

View post on LinkedIn

Absci 1w ago

We’re proud to share a recent highlight from our partnership with AMD: a dedicated AMD Instinct™ MI300X cluster, now deployed for Absci’s AI drug discovery platform in service of our mission to accelerate AI antibody design and discovery.

View post on LinkedIn